A robust gene expression signature to predict proteasome inhibitor benefit in Multiple Myeloma

Joske Ubels, Pieter Sonneveld, Martin H. van Vliet, Jeroen de Ridder
doi: https://doi.org/10.1101/2019.12.16.19015024

Article Information

doi 
https://doi.org/10.1101/2019.12.16.19015024
History 
  • December 19, 2019.
Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Author Information

  1. Joske Ubels1,2,3,4,*,
  2. Pieter Sonneveld3,
  3. Martin H. van Vliet4 and
  4. Jeroen de Ridder1,2
  1. 1Center for Molecular Medicine, University Medical Center Utrecht, Universiteitsweg 100, 3584 CG, Utrecht, The Netherlands
  2. 2Oncode Institute, Utrecht, The Netherlands
  3. 3Department of Hematology, Erasmus MC Cancer Institute, Wytemaweg 80, 3015 CN, Rotterdam, The Netherlands
  4. 4SkylineDx, Lichtenaurlaan 40, 3062 ME, Rotterdam, The Netherlands
  1. ↵*corresponding author email: j.ubels{at}umcutrecht.nl
Back to top
Posted December 19, 2019.
Download PDF
Data/Code
Email
A robust gene expression signature to predict proteasome inhibitor benefit in Multiple Myeloma
Joske Ubels, Pieter Sonneveld, Martin H. van Vliet, Jeroen de Ridder
medRxiv 2019.12.16.19015024; doi: https://doi.org/10.1101/2019.12.16.19015024
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area